Ocular Therapeutix plans AXPAXLI wet AMD NDA on SOL-1 data, not SOL-R efficacy
The Q4 2026 filing drops SOL-R's own year-one efficacy data from the package, leaning on SOL-1 results while SOL-R shifts to test superiority over high-dose aflibercept at Week 96.
Executive Summary
- Ocular Therapeutix intends to submit its wet AMD NDA using one trial's efficacy data plus a safety-only contribution from its second pivotal study, a narrower basis than originally planned.
- The second trial's own efficacy results, once intended to support the same filing, are being pulled out and redirected toward a later, higher bar against a higher-dose competitor regimen.
- Removing that trial's efficacy data from the near-term filing accelerates the submission timeline but concentrates the efficacy case on a single study, with the second trial's readout now arriving after the FDA decision would land.
- No competitor in the indication shares this implant's small-molecule tyrosine kinase inhibitor mechanism, leaving the asset without a direct precedent to benchmark its filing strategy against.
The decision
At a June 17, 2026 investor day, Ocular Therapeutix disclosed that the FDA aligned on an AXPAXLI NDA for wet AMD in the fourth quarter of 2026 under the 505(b)(2) pathway, which references existing safety data for a previously approved drug and can shorten review by up to 60 days. The filing will rest on SOL-1 Week 52 efficacy and safety data combined with an interim SOL-R safety analysis designed to reach more than 300 combined patients across both trials. That interim analysis is scheduled for the fourth quarter of 2026, the same window as the planned filing. OcularOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with ...Jun 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What SOL-R gives up
SOL-R's own efficacy data will not be part of the NDA package, a reversal from the trial's original registrational role. The FDA had told Ocular in an August 2024 Type C response that SOL-R, as a repeat-dosing Phase 3 study of intravitreal axitinib against aflibercept, was appropriate as the company's second adequate and well-controlled study to support an NDA. Instead, Ocular is amending SOL-R to extend masking through Week 96 and add a new secondary endpoint testing superiority in best-corrected visual acuity against aflibercept dosed at 8 mg every six months, alongside a comparison against the 2 mg dose already in the label for differentiation purposes. Topline data from SOL-R, now testing a higher efficacy bar than originally designed, are expected in the first quarter of 2028, more than a year after the SOL-R readout the company had guided to just one quarter earlier: its first-quarter 2026 disclosure had pointed to a Q1-2027 topline readout for the trial. OcularOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with ...Jun 17, 2026
Trial mechanics
SOL-R (NCT06495918) is a Phase 3, randomized, active-comparator trial of the AXPAXLI axitinib implant against aflibercept in treatment-naive and recently diagnosed wet AMD patients, with best-corrected visual acuity as the sole registered primary endpoint. The trial targets 825 patients, runs across the United States, Argentina, Australia, and Puerto Rico, and has held that enrollment target unchanged since its 2024 initial posting. It moved from recruiting to active, not recruiting, in June 2025, and its registered primary completion date remains January 8, 2027, three to six months later than the fourth-quarter-2026 window the company has now set for the interim safety cut and the NDA filing itself. No results have posted to the trial's registry record. NCT06495918Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918
The competitive field
AXPAXLI's mechanism, a tyrosine kinase inhibitor delivered as an intravitreal implant, has no approved comparator sharing that combination of target class and delivery format among trials in wet AMD tracked here; the nearest neighbors, including Roche's ranibizumab and AbbVie's gene-therapy candidate surabgene lomparvovec, work through different mechanisms entirely. Ocular's own second Phase 3 axitinib implant trial (NCT07516132) is the closest precedent, sharing modality and target but not yet resolved. Standard of care in wet AMD runs on repeat intravitreal anti-VEGF injections, and the durability claim behind AXPAXLI's implant format is the differentiation the company is building its label strategy around: a single trial's efficacy data now carries the near-term filing, while the second trial is repositioned to test a higher bar, superiority over an 8 mg aflibercept regimen, for future label expansion. OcularOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with ...Jun 17, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.